ADHD Drug Trial Results Have Shown Promise
A new medication targeting the brain's orexin system helped adults manage ADHD symptoms in an early clinical study.
Updated on Sept. 25, 2026 in Allergies
Live Poll
Would you trust a non-stimulant medication to manage ADHD symptoms more than traditional stimulant drugs?
Researchers recently released results from a clinical trial of the experimental ADHD drug ALKS 7290, which showed significant improvement in adult symptom management. The medication acts on the brain's orexin system to regulate attention and wakefulness, offering a potential alternative to traditional stimulants.
Why it matters
Many existing ADHD treatments rely on stimulants that increase dopamine and noradrenaline levels, which can carry risks like high blood pressure and potential for misuse. This new approach aims to address core symptoms while avoiding the cardiovascular side effects common with standard stimulant therapies.
In an early-stage clinical trial of 50 adults, participants receiving ALKS 7290 showed a transition from severe to mild ADHD ratings over two weeks compared to a placebo. These findings are preliminary, and researchers are now launching a larger trial involving more than 300 patients.
The players
Virginia Tech
A major research university and the institution housing the research team that conducted the ALKS 7290 study.
The details
ALKS 7290 functions by stimulating the brain's orexin system, a network of neurons responsible for controlling wakefulness, arousal, and sustained attention. Unlike traditional stimulants, this mechanism does not directly spike dopamine or noradrenaline levels. While the initial study reported improvements in hyperactivity and inattention, participants did experience side effects including insomnia, dizziness, constipation, and frequent urination.
Timeline
Last week, researchers released the initial clinical trial results.
The clinical trial spanned a duration of two weeks.
The medication could be commercially available within five years.
Health Landscape
This development represents an expansion of orexin-targeting technology, which has primarily been researched for sleep and alertness disorders, into the treatment of neurodevelopmental conditions. It signals a potential shift away from the stimulant-based standard of care that has dominated ADHD management for decades.
These preliminary findings do not change current treatment paths for ADHD and should not be interpreted as a recommendation for any specific therapy. If you have concerns about your current ADHD medication or its side effects, consult your physician to discuss potential alternatives or adjustments.
The takeaway
Early results suggest that targeting the orexin system may help manage ADHD symptoms without the cardiovascular risks associated with traditional stimulants. Patients interested in evolving treatment options should track major trial updates and speak with their doctor about current management strategies.
What happens next
A larger clinical trial involving more than 300 patients is currently underway to further evaluate the efficacy and safety profile of the medication.
Further reading
For broader context on managing neurodevelopmental care, visit our Allergies section.
Live Poll
Would you trust a non-stimulant medication to manage ADHD symptoms more than traditional stimulant drugs?
